According to the Zhitong Finance App, the US and China Jiahe (02453) announced the results for the year ended December 31, 2023, with revenue of 539 million yuan (RMB, same below), up 14.1% year on year; the Group's hospital business revenue increased 46.5% year over year to 320 million yuan, mainly due to increased brand awareness and growing medical demand.

The Group is actively involved in the field of oncology medicine. It has successfully established or acquired six offline self-operated medical institutions, and is committed to providing comprehensive and specialized medical services to cancer patients. These institutions are mainly located in Guangzhou and Shanghai, covering the Greater Bay Area and the Yangtze River Delta, bringing timely and warm medical care to many patients.

The Group's medical institutions have achieved remarkable results in various fields. In particular, in terms of tumor radiotherapy, the Group has made it an advantageous discipline to continuously strengthen clinical diagnosis and treatment capacity building. As the Group's chief radiotherapy expert, Professor Fu Shen successfully led the application for the “Clinical Application and Establishment of a Clinical Quality Control and Translational Research System Based on Frontier Proton Radiotherapy Technology” and was successfully approved as a “Guangzhou Regional Clinical Special Technology Project”, which undoubtedly lays a solid foundation for the Group's research and practice in the field of tumor radiation therapy. During the year, the book “Proton Therapy: Indications, Techniques and Efficacy” (Proton Therapy: Indications, Techniques and Efficacy), with the participation of Professor Fu Shen, the Group's chief physicist, and Professor Li Zuofeng, the group's chief physicist, was officially distributed by the People's Health Press. As an essential professional reference book in the field of proton therapy, it will definitely play an important role in improving the level of diagnosis and treatment of proton therapy and radiation oncology in China, promoting the standardization process of proton therapy and the popularization and application of modern accurate radiotherapy.

At the same time, the Group is also pleased to see the improvement in clinical diagnosis and treatment capabilities. In 2023, the number of people treated increased by 55% compared to 2022, and the number of systemic radiotherapy cases exceeded 170. Furthermore, the Group completed clinical trials of proton therapy in 2023, and is expected to use the world's leading proton therapy technology in 2024 to benefit more patients.

Oncology surgery is the focus of hospital discipline construction, and the Group is committed to making specialty specialties and characteristic diseases the highlight of the subject brand. In terms of breast surgery, in 2023, the group achieved remarkable results with a breast retention rate of more than 40%, and successfully performed a difficult subabdominal artery piercing operation (DIEP). In 2023, in terms of general surgery, the number of surgeries increased by 16.3%, with grade 3 and 4 surgeries accounting for 76%, which fully demonstrates the Group's professional strength in the field of complex surgery.

It is worth mentioning that in the face of multiple uncertainties after the 2023 pandemic, policies, and the international economic environment, the Group has not only achieved remarkable achievements in the medical business, but also made significant progress in supply chain expansion and 5G+ business innovation. In terms of supply chain, the Group has successfully expanded and signed new projects for 40 hospitals. At the same time, the Group is also actively shifting to diversified cooperation, meeting the diverse needs of customers and injecting new impetus into the Group's continuous development.

In terms of 5G+ business development, the Group has achieved remarkable results. By signing Jiahe Cloud Platform Empowerment Cooperation Agreements with several hospitals, the Group successfully provided partners with a series of innovative solutions such as remote radiotherapy technical support, digital imaging services, remote magnetic resonance diagnosis, and artificial intelligence (AI) diagnosis services. These collaborations have not only significantly improved the efficiency and efficacy of cancer treatment, provided a solid guarantee for the daily diagnosis and treatment of primary medical institutions, but also fully demonstrated the Group's innovative capabilities and market competitiveness in the 5G+ medical field. Through these successful cooperation cases, the Group has further consolidated its leading position in the industry and laid a solid foundation for further development in the 5G+ medical field in the future.